Research

Research
The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Research in IMO

The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Ongoing projects

In the field of clinical research, the objective of projects currently under development is not only to improve the prognosis of patients with certain diseases, but also to offer, for the first time, an effective solution to diseases that are currently untreatable. This is also the ultimate goal of genetic studies, whose aim is to provide in-depth analysis of already known genes and identify new genes related to retinal dystrophies.
Investigación básica

Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies

Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.

Investigación clínica

Artemis

Efficacy and safety of slow-release bimatoprost in patients with open-angle glaucoma or ocular hypertension.

Investigación clínica

Biotek-Padciclo

Phase II, multicentre, randomised, double-masked, 4 parallel arms, controlled, 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients.

Project history

The ophthalmologists, optometrists and nurses who specialise in ocular photography at the IMO carry out several multicentre clinical trials a year, of which the IMO is often the coordinator or main leading centre in Spain. These trials join the pioneering projects carried out by the genetics laboratory.
Investigación clínica

Aqua

Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.